Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F19%3AN0000129" target="_blank" >RIV/00098892:_____/19:N0000129 - isvavai.cz</a>

Result on the web

<a href="https://www.nature.com/articles/s41375-019-0487-8" target="_blank" >https://www.nature.com/articles/s41375-019-0487-8</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41375-019-0487-8" target="_blank" >10.1038/s41375-019-0487-8</a>

Result language

angličtina

Original language name

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Original language description

We conducted a large international nested case-control study including 1881 patients with Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration. The aim was to evaluate the risk of SC after exposure to cytoreductive drugs. Patients exposed to hydroxyurea (HU) (median: 3 years) had a risk of SC similar to unexposed patients (OR = 1.06, 95% CI 0.82-1.38). In contrast, in cancer-specific stratified multivariable analysis, HU had two-fold higher risk of non-melanoma (NM) skin cancer (OR = 2.28, 95% CI 1.15-4.51). A significantly higher risk of NM-skin cancer was also documented for pipobroman (OR = 3.74, 95% CI 1.00-14.01), ruxolitinib (OR = 3.87, 95% CI 1.18-12.75), and for drug combination (OR = 3.47, 95% CI 1.55-7.75). These three drugs did not show excess risk of carcinoma and hematological second cancer compared with unexposed patients. Exposure to interferon, busulfan, and anagrelide did not increase the risk. In summary, while it is reassuring that no excess of carcinoma was documented, a careful dermatologic active surveillance before and during the course of treatments is recommended.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

LEUKEMIA

ISSN

0887-6924

e-ISSN

1476-5551

Volume of the periodical

33

Issue of the periodical within the volume

8

Country of publishing house

GB - UNITED KINGDOM

Number of pages

10

Pages from-to

1996-2005

UT code for WoS article

000479118400013

EID of the result in the Scopus database

2-s2.0-85066502819